Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2024-05-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
北京双鹭药业股份有限公司第九届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the first meeting of the ninth board of directors of Beijing SL Pharmaceutical Co., Ltd. It details the election of the chairman, appointment of board committees, and hiring of senior management personnel. The content focuses on board and management changes, including names, roles, terms, and qualifications of the appointed individuals. There is no financial data, earnings information, or report publication mentioned. The document is not a report itself but an official announcement of board and management decisions. Therefore, it fits the category of Board/Management Information (MANG). The document length is about 4994 characters, which is sufficient for a detailed announcement but not a full report.
2024-05-23 Chinese
第九届董事会独立董事专门会议第一次会议审核意见
Board/Management Information Classification · 95% confidence The document is a formal meeting opinion from the independent directors of the ninth board of Beijing Shuanglu Pharmaceutical Co., Ltd. It details the convening of a special meeting of independent directors and their review and approval of the appointment of senior management personnel. The content focuses on board/management matters, specifically the appointment of senior management, and does not contain financial data or audit information. It is not an announcement of a report but a board-related decision. Therefore, the appropriate classification is 'Board/Management Information' (MANG). The document length is short but contains substantive content about management appointments, not just an announcement or certification.
2024-05-23 Chinese
北京双鹭药业股份有限公司2023年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2023 年度财务决算报告' which translates to '2023 Annual Financial Settlement Report'. It contains detailed financial data including total assets, liabilities, net assets, revenue, profit, cash flow, and comparative figures for 2022 and 2023. The document is comprehensive and includes actual financial statements and analysis for the full fiscal year 2023. The length is 1657 characters, which is relatively short but the content is substantive financial data rather than a mere announcement or certification. The document is clearly a full annual financial report rather than an announcement or a certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-04-23 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 8th Board of Directors of Beijing SL Pharmaceutical Co., Ltd. It includes multiple agenda items such as approval of the 2023 Annual Report and its summary, the 2023 Board Work Report, the 2023 General Manager Work Report, the 2023 Financial Final Accounts Report, the 2023 Profit Distribution Plan, the 2023 Internal Control Self-Evaluation Report, the 2023 Social Responsibility Report, the 2024 Q1 Report, and other governance and management related reports. The document also discusses nominations for the 9th Board of Directors and amendments to the company bylaws. The document is not the actual annual report or financial statements but a board meeting resolution announcement that these reports have been reviewed and approved to be submitted to the 2023 Annual General Meeting for shareholder approval. It also includes voting results for each agenda item. The document length is 7589 characters, which is substantial but the content is clearly a board meeting resolution announcement rather than the full reports themselves. Therefore, this document fits best into the category of Board/Management Information (MANG) as it announces board meeting decisions, including approval of reports and nominations, rather than the reports themselves or shareholder meeting materials.
2024-04-23 Chinese
北京双鹭药业股份有限公司章程（2024.04）
Governance Information Classification · 100% confidence The document is titled as the "章程" (Articles of Association or Company Bylaws) of Beijing SL Pharmaceutical Co., Ltd., dated April 2024. It contains detailed provisions on company organization, shareholder rights, board of directors, management, shares issuance, shareholder meetings, voting procedures, and other governance matters. It is a comprehensive governance document that outlines the internal rules and structure of the company rather than a financial report, audit, or announcement. There is no indication that this is an annual report, earnings release, or any other financial filing. The content matches the description of Governance Information, which covers the company's internal rules, board structure, and governance practices.
2024-04-23 Chinese
北京双鹭药业股份有限公司对外提供财务资助管理办法（2024.04）
Governance Information Classification · 95% confidence The document is titled '对外提供财务资助管理办法' (Measures for External Financial Assistance Management) and is a detailed internal policy document of Beijing Shuanglu Pharmaceutical Co., Ltd. It outlines rules, approval procedures, responsibilities, and disclosure requirements related to the company's provision of financial assistance to external parties. It references regulatory frameworks and stock exchange rules but does not contain financial statements, earnings data, or audit results. It is a governance or internal control policy document rather than a financial report, announcement, or regulatory filing. The document length is 3866 characters, which is relatively short but contains substantive policy content rather than a brief announcement. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2024-04-23 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.